Active	Status	Sponsor type	Region	Phase	Filter
1 Active 0 Inactive 1 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Elenkova, Atanaska
ACSPIRE, NCT05436639 / 2022-000748-32: SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor	Active, not recruiting	2	30	Europe, US	SPI-62 dose	Sparrow Pharmaceuticals, Sparrow Pharmaceuticals, Inc.	Autonomous Cortisol Secretion (ACS), ACTH-Independent Cushing Syndrome, ACTH-Independent Adrenal Cushing Syndrome, Somatic	12/24	12/25